[1] 中华医学会核医学分会,中华医学会泌尿外科分会.前列腺癌 PSMA PET 显像临床应用中国专家共识 (2025 版)[J]. 中华核医学与分子影像杂志,2025, 45: 81-90. [2] 中国抗癌协会泌尿男生殖系统肿瘤专业委员会.中国前列腺癌诊疗指南 2024 版[J]. 中华泌尿外科杂志,2024, 45: 321-330. [3] Mazzone E, Fossati N, Gandaglia G, et al. The role of PSMA PET/CT in primary staging of prostate cancer: a systematic review and Meta-analysis[J]. Eur Urol, 2025, 87: 654-671. [4] Hoffman A, Amiel GE. The impact of PSMA PET/CT on modern prostate cancer management and decision making—the urological perspective[J]. Cancers, 2023, 15: 3402.doi:10.3390/cancers15133402. [5] 王一帆,李鸣,周利群. PSMA PET/CT 与多参数 MRI 在中高危前列腺癌术前分期中的对比研究[J]. 中华泌尿外科杂志,2023, 44: 592-597. [6] Tilki D, Bossi A, Briganti A, et al. EAU-EANM-ESTRO-ESUR-ISUP guidelines on prostate cancer 2024 update: imaging and staging recommendations[J]. Eur Urol Focus, 2024, 10: 1012-1025. [7] Gafita A, Rauscher I, Weber M, et al. RECIP 1.0: international multicenter framework for PSMA PET treatment response evaluation in mCRPC[J]. J Nuc Med, 2022, 63: 1651-1658. [8] 黄伟鹏,王雪梅. PSMA PET/CT 在前列腺癌生化复发定位诊断中的应用进展[J]. 中华核医学与分子影像杂志,2024, 44: 189-193. [9] Calais J, Kishan AU, Cao M, et al. Impact of Ga-PSMA-11 PET/CT on definitive radiation therapy planning for prostate cancer[J]. J Nucl Med, 2018, 59: 1714-1721. [10] Sofia L, Gallo F, Boccardo F, et al. PSMA PET/CT in low-to intermediate-risk prostate cancer: clinical indication and value[J]. Asian J Androl, 2024, 26: 584-586. [11] 刘辰,叶定伟.精准影像指导下前列腺癌个体化治疗策略进展[J]. 中国癌症杂志,2023, 33: 561-568. [12] Arnfield EG, Roberts MJ, Pattison DA, et al. Standardi-zed lymph node classification for PSMA-PET: E-PSMA reporting guideline validation[J]. Eur J Nucl Med Mol Imaging, 2023, 50: 8-9. [13] Huang WP, Hsu JC. PSMA PET-directed radiotherapy for prostate cancer: from precision planning to future innovations[J]. VIEW, 2025, 1: 20250143. doi:10.1002/VIW.20250143. [14] Wang YF, Lo CY, Chen LY, et al. Diagnostic efficacy comparison of mpMRI and PSMA PET/CT for clinically significant prostate cancer: a systematic review and meta-analysis[J]. BMC Cancer, 2023, 23: 1124. doi:10.1186/s12885-023-11124-x. [15] 陈钰,张芳,李建刚. F-DCFPyL 与 Ga-PSMA-11 PET/CT 在前列腺癌诊断中的应用对比[J]. 临床放射学杂志,2024, 43: 891-895. [16] Berenggren O, Pekala KR, Matsoukas K, et al. Epidemiology and risk factor updates of prostate cancer 2022[J]. Eur Urol, 2023, 84: 191-206. [17] Mazzone E, Briganti A. PSMA PET for biochemical recurrence of prostate cancer: management impact and survival outcomes[J].Curr Opin Urol, 2024, 34: 98-105. [18] 中华医学会泌尿外科分会肿瘤学组.前列腺癌根治术后生化复发诊疗规范 (2024 版)[J]. 中华泌尿外科杂志,2024, 45: 561-567. [19] Vargas HA, Fanti S, Herrmann K, et al. Standardization of PSMA PET/CT interpretation for prostate cancer clinical trials[J]. Radiology, 2023, 307: 250701. doi:10.2967/jnmed.117.198119. [20] 赵宇,王浩,孙光.人工智能辅助 PSMA PET/CT 诊断前列腺癌的研究进展[J]. 医学影像学杂志,2025, 35: 156-159. |